Declan Doogan's motivation for leaving a 25-year career at Pfizer wasn't just to start one company. He sought "agency"—the freedom from being tied to a single large employer, enabling him to engage in a broad portfolio of partnerships and ventures in the more dynamic and exciting startup world.
Related Insights
Seneca's founder turned down lucrative offers to run larger companies. For him, the unique, "insanely gratifying" value of founding is the ability to create the mission from scratch and dedicate his life force to a specific desired change in the world, a power not available in an existing CEO role.
The firm’s core belief is being a fund *for* founders, trusting them to run their companies without heavy operational input. This hands-off approach gives partners the bandwidth and "permission" to go deep on their own projects, leading to spinouts like Anduril and Varda.
The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.
Beyond financial incentives, personal ego and the desire to build an independent legacy can be powerful and valid motivators for spinning out to start a new venture firm, even when leaving a successful family operation.
A primary motivator for many successful entrepreneurs isn't just the desire to build something new, but a fundamental incompatibility with corporate structure. This craving for autonomy makes entrepreneurship less of a career choice and more of a personal necessity, a powerful 'push' factor away from traditional employment.
Beyond financial incentives or strategic differences, a primary driver for a successful partner to spin out from an established firm can be pure ego. The desire to build something independently and prove one's own success is a powerful, albeit rarely admitted, motivation for starting a new venture.
Rather than viewing his long tenure at Pfizer as the final destination, Doogan frames it as a crucial learning period. This "apprenticeship" provided invaluable experience with drug development, failure, and industry dynamics, which directly enabled his later success as a biotech founder and executive.
ProPhet was founded through Ion Labs, a venture studio created by AstraZeneca, Merck, Pfizer, and Teva. This model allows established pharmaceutical giants to identify acute internal challenges and recruit external talent to build dedicated startups aimed at solving them.
Despite Meta offering nine-figure bonuses to retain top AI employees, its chief AI scientist is leaving to launch his own startup. This proves that in a hyper-competitive field like AI, the potential upside and autonomy of being a founder can be more compelling than even the most extravagant corporate retention packages.
Kenai CEO Nick Manusos attributes his startup success to his varied background at Abbott Labs, moving from manufacturing to sales to BD. This breadth prepared him to handle the multifaceted demands of a startup, where a leader must be a generalist who is comfortable with constant change.
